Necessity of genetic testing before pemetinib/pemetinib treatment

Pemigatinib/Pemigatinib is a potent and selective small molecule inhibitor that mainly targets fibroblast growth factor receptors (FGFR1, FGFR2 and FGFR3). It is excellent in the treatment of cholangiocarcinoma (CCA), especially in patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma and FGFR2 genomic abnormalities (such as fusions, rearrangements). Due to its remarkable efficacy, the FDA has designated it as an orphan drug for the treatment of cholangiocarcinoma.

However, treatment with pemetinib is not suitable for all patients with cholangiocarcinoma. To ensure the effectiveness and accuracy of treatment, doctors often recommend genetic testing before pemetinib treatment. The core purpose of genetic testing is to determine whether specific FGFR gene mutations are present in a patient's tumor, and these mutations are closely related to the sensitivity of pemetinib.

Through advanced genetic testing technologies, such as next-generation sequencing (NGS) or fluorescence in situ hybridization (FISH), patients' tumor tissue or blood samples can be analyzed to look for specific variations in the FGFR gene. These test results will provide doctors with important information to help them determine whether a patient is a candidate for pemetinib treatment.

Genetic testing plays a vital role in personalized medicine. It can not only guide doctors to choose the best treatment plan for patients, but also predict the likely effects of treatment. Therefore, genetic testing is an essential step for patients considering pemetinib to help ensure that patients receive the treatment that is best for them and to maximize the effectiveness of treatment.